A carregar...
Is immunotherapy in the future of therapeutic management of sarcomas?
Sarcomas are rare, ubiquitous and heterogeneous tumors usually treated with surgery, chemotherapy, target therapy, and radiotherapy. However, 25–50% of patients experience local relapses and/or distant metastases after chemotherapy with an overall survival about 12–18 months. Recently, immuno-therap...
Na minha lista:
| Publicado no: | J Transl Med |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8077947/ https://ncbi.nlm.nih.gov/pubmed/33902630 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-021-02829-y |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|